An interventional study of GRAIL Galleri Test in Cancer Predisposition Syndrome and Predisposition, Genetic, sponsored by Dana-Farber Cancer Institute. Recruiting at 1 site in United States. Open to participants aged 22 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-01-20.
Sponsored by Dana-Farber Cancer Institute · Not applicable, Interventional, and Screening
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 87 studies in Genetic Predisposition to Disease with a site in United States — 37 open to participants now, 46 under way, none of them phase 3. Genetic Predisposition to Disease · United States.
Among the 87 studies in Genetic Predisposition to Disease with a site in United States, this one is the 9th largest by planned enrollment of the 37 interventional ones that give a count, is one of 7 that started in 2024, is one of 30 with no phase, reaches primary completion later than 10 of the 45 other live ones, and was the 71st registered.
242 studies on the registry are indexed under Genetic Predisposition to Disease; 96 are open to participants now.
Browse Genetic Predisposition to Disease studies →37 of the 87 studies in Genetic Predisposition to Disease with a site in United States are open now. Recruiting first, the newest first:
University of Missouri-Columbia · Sites in United States
Ages 45–65 · Women only · Healthy volunteers
St. Jude Children's Research Hospital · Sites in United States
Ages 18+
Georgetown University · Sites in United States
Ages 45–74 · Women only · Healthy volunteers
Duke University · Sites in United States
Ages 18+ · Women only
Christopher Reilly · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 71 Genetic Predisposition to Disease studies recruiting now, 36 (51%) set no upper age limit and 28 (39%) stop at 75 or younger; 25 take children under 18; 23 take healthy volunteers.
This study: 22 Years and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
87 studies; the count open now beside each. This study's row is marked.
First in 1995; this study’s year is marked. 7 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 1,000 is above the median of 238 across 86 interventional studies indexed under Genetic Predisposition to Disease.
Median enrollment 225 across the 37 interventional studies, 560 across the 50 observational. Of the 36 that completed or were terminated, 9 (25%) have results posted.
This tab as a report to print or save as PDF → With an account.
3 of 87 have an industry lead sponsor. The 10 most frequent:
Dana-Farber Cancer Institute is the lead sponsor of 836 studies on the registry; 121 are open to participants now.
Of its 114 completed or terminated interventional studies of FDA-regulated products, 78 (68%) have results posted.
Dana-Farber Cancer Institute has 3 studies filed under Genetic Predisposition to Disease — fewer than ten, so there is no comparison to draw.
13 of the studies in Genetic Predisposition to Disease with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05205356Boston Children's HospitalVIGOR: Virtual Genome Center for Infant Health | 2026-12-31 |
| NCT05020574University of California, San FranciscoMicrobiome and Association With Implant Infections | 2026-12-31 |
| NCT06962059Abramson Cancer Center at Penn MedicineHealthy Volunteers Study | 2027-01-15 |
| NCT06450171Dana-Farber Cancer InstituteEvaluation of Multi-Cancer Early Detection Testing in a High-Risk Population: The INFORM Study | 2027-01-31 |
| NCT05161169Brigham and Women's HospitalImplementation of Whole Genome Sequencing as Screening in a Diverse Cohort of Healthy Infants | 2027-04 |
Add all 13 to your calendar (.ics) → With an account.
Among the 87 studies in Genetic Predisposition to Disease with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this research study is to evaluate the possible benefits and harms of screening with an investigational blood test designed to detect many types of cancer early.
The name of the screening blood test being studied is:
-GRAIL Galleri test
This is a prospective, interventional study to assess the use of the GRAIL's Galleri multi-cancer early detection (MCED) Test, an investigational blood test designed to detect many types of cancer, for participants that are considered at slightly higher than average risk of developing certain types of cancers. The test looks for small pieces of genetic material called deoxyribonucleic acid (DNA) in the blood that may indicate the presence of cancer.
The research study procedures include screening for eligibility, blood tests, questionnaires, and clinic visits.
Participation in this research study is expected to last up to 3 years.
It is expected that about 1,000 people will take part in this research study.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Inclusion Criteria Group 1- Cancer Predisposition Syndrome:
Inclusion Criteria Group 2 - Familial Risk:
Adults with family history suggestive of elevated cancer risk as defined by any the criteria below, who do not fall into Group 1:
≥ 1 first or second degree relative on same side of the family with:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will be enrolled and will complete: * Baseline questionnaires and blood test. * Post-test questionnaires. * Follow-up assessments for a negative GRAIL Galleri test include recommended cancer screenings and a follow up phone call with study staff 1 year after the GRAIL Galleri blood test. * Follow-up assessments for a positive GRAIL test may include clinic visits, lab tests with additional blood work-ups, biopsies, surgical procedures, or imaging assessments such as ultrasound, Computed Tomography (CT) scans, or an Magnetic Resonance Imaging (MRI) scans. * If cancer status is confirmed, participants will complete a post-diagnostic questionnaire.
Other: GRAIL Galleri Test
A multi-cancer early detection (MCED) blood test.
Cancer Detection Rate
Descriptive statistics will be used to summarize the number and types of cancers diagnosed by GRAIL Galleri MCED testing.
Time frame: Up to 2 years
Stage of Invasive Cancer Diagnosis
Descriptive statistics will be used to summarize the stages of invasive cancer that are diagnosed by GRAIL Galleri MCED testing and assessed by medical record review.
Time frame: Up to 2 years
Positive Predictive Value At 12 Months
Positive Predictive Value is defined as the proportion of participants with cancer diagnosis out of all participants with "signal detected" on GRAIL Galleri MCED test results.
Time frame: At 12 months
Positive Predictive Value at 24 Months
Positive Predictive Value is defined as the proportion of participants with cancer diagnosis out of all participants with "signal detected" on GRAIL Galleri MCED test results.
Time frame: At 24 months
Time to Diagnostic Resolution
Defined as the time required to achieve diagnostic resolution following a "signal detected" GRAIL Galleri MCED test result.
Time frame: Calculated from the date of return of screening results (up to 4 weeks from baseline) until up to 24 months post screening
Test Type Utilization to Diagnostic Resolution
Per participant the count of the number and types of diagnostic tests required to achieve diagnostic resolution following a "signal detected" GRAIL Galleri MCED test result.
Time frame: Up to 24 months
Change in Participant Anxiety
Changes in anxiety following the GRAIL Galleri MCED test result and assessed by the Patient-Reported Outcome Measurement Information System (PROMIS) Emotional Distress Anxiety - Short Form 6a, which is a 6 item survey that is rated on a 5-point Likert scale with answers ranging from "Never" to "Always". The range of scoring is from 6 to 30 with higher scores indicating greater severity of anxiety.
Time frame: Up to 24 months
Change in Participant Health-related Quality of Life
Changes in health-related quality of life following the GRAIL Galleri MCED test result and assessed by PROMIS Scale v1.2 - Global Health, a 10 item survey that is rated on a 5-point Likert scale with answers ranging from "Excellent/Completely/Never/None" to "Poor/Not at all/Always/Very Severe" and includes a pain average question rated on a scale of 0 "No Pain" to 10 "Worst Pain Imaginable." The range of scoring is from 9 to 45 with higher scores indicating higher quality of life.
Time frame: Up to 24 months
Cost of Follow-up Testing
Defined as the dollar cost, per participant, of follow-up testing to achieve diagnostic resolution following a "signal detected" GRAIL Galleri MCED test result.
Time frame: Up to 24 months
Institutional Reimbursement of Follow-up Testing
Defined as the dollar cost, per participant, of the institutional reimbursement of follow-up testing to achieve diagnostic resolution following a "signal detected" GRAIL Galleri MCED test result.
Time frame: Up to 24 months
Plan to share: Yes — The Dana-Farber / Harvard Cancer Center encourages and supports the responsible and ethical sharing of data from clinical trials. De-identified participant data from the final research dataset used in the published manuscript may only be shared under the terms of a Data Use Agreement. Requests may be directed to: [contact information for Sponsor Investigator or designee]. The protocol and statistical analysis plan will be made available on Clinicaltrials.gov only as required by federal regulation or as a condition of awards and agreements supporting the research.
Supporting information: Study protocol, Statistical analysis plan
Time frame: Data can be shared no earlier than 1 year following the date of publication
Access criteria: Contact the Belfer Office for Dana-Farber Innovations (BODFI) at innovation@dfci.harvard.edu
No publications or documents are linked to this record.
Started Sep 2024 (actual). Primary completion is estimated for Jan 2027, 28 months after the start.
Of 57 non-industry interventional studies with no phase under Genetic Predisposition to Disease, half reached primary completion within 36 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 128. This study's planned 28 months is below that.
Counting every sponsor, half of 57 studies reached it within 36 months; a quarter within 18 and three quarters within 128.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Genetic Predisposition to Disease →
Dana-Farber Cancer Institute →